Drug Combination Details
| General Information of the Combination (ID: C79321) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Simvastatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Bladder cancer
[ICD-11: 2C94]
|
Phase 2 | [1] | ||
|
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [2] | |||
|
Uterine cancer
[ICD-11: 2C76]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | RL95-2 | CVCL_0505 | Endometrial adenosquamous carcinoma | Homo sapiens | ||
| HEC-1-B | CVCL_0294 | Endometrial adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | PC-3 D12 | CVCL_4Y40 | Prostate carcinoma | Homo sapiens | ||
| LNCaP C4-2B5 | CVCL_4788 | Prostate carcinoma | Homo sapiens | |||
| LNCaP C4-2B4 | CVCL_4787 | Prostate carcinoma | Homo sapiens | |||
| LNCaP C4-2B3 | CVCL_4786 | Prostate carcinoma | Homo sapiens | |||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Male NCr-nu/nu mice were used in this study. | |||||
| Experimental
Result(s) |
Combination of simvastatin and metformin, within pharmacologic dose range (500 nmol/L to 4 umol/L simvastatin and 250 umol/L to 2 mmol/L metformin), significantly and synergistically reduces C4-2B3/B4 CRPC cell viability and metastatic properties, with minimal adverse effects on normal prostate epithelial cells. | |||||
